Dr. Alan Corin earned an A.B. in Chemistry and Biochemistry from Bowdoin College and an M.S. and Ph.D. in Chemistry from Columbia University.
After a postdoctoral fellowship at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany he accepted a staff scientist position in the Research Laboratories at Eastman Kodak Co. in Rochester, NY and held a principal investigator position in the NSF Science and Technology Center for Photo-induced Charge Transfer processes, a center of excellence collaboration established between Xerox, Kodak and the University of Rochester.
Since moving to the Boston area Dr. Corin has held various R&D positions including:
Dr. Corin was recently a Senior Director of Biochemistry and Molecular Pharmacology at Bristol Meyers Squibb having served in this role for nearly ten years at Celgene prior to the BMS purchase of Celgene. At Celgene he directed biochemical assay development, mechanism of action studies and proteomics activities, all aimed at developing covalent drugs and elucidating how they work in cells. During that time, he also led the new targets initiative and, as an active participant himself, proposed a target strategy to prosecute the target MAPKAP2 (MK2) for autoimmune and inflammatory diseases. A covalent MK2 inhibitor, CC-99677, developed from those efforts is currently in Ph 2 trials for ankylosing spondylitis.
After leaving BMS, Dr. Corin has been advising small biotechnology companies, venture capital, and The Harrington Discovery Institute on the art of drug discovery.